The Oncology Institute, Inc. (NASDAQ:TOI) Short Interest Up 29.8% in June

The Oncology Institute, Inc. (NASDAQ:TOI) was the target of a significant increase in short interest in the month of June. As of June 30th, there was short interest totalling 301,800 shares, an increase of 29.8% from the June 15th total of 232,600 shares. Based on an average trading volume of 168,500 shares, the short-interest ratio is currently 1.8 days. Approximately 1.0% of the company’s stock are sold short.

Institutional Trading of Oncology Institute

Hedge funds and other institutional investors have recently made changes to their positions in the business. Kent Lake Capital LLC boosted its holdings in Oncology Institute by 492.3% during the fourth quarter. Kent Lake Capital LLC now owns 1,085,171 shares of the company’s stock worth $2,214,000 after purchasing an additional 901,956 shares during the last quarter. Cincinnati Insurance Co. bought a new stake in Oncology Institute during the fourth quarter worth about $1,427,000. FourWorld Capital Management LLC bought a new position in Oncology Institute in the first quarter valued at approximately $396,000. Fielder Capital Group LLC acquired a new position in shares of Oncology Institute during the 4th quarter worth approximately $143,000. Finally, Quattro Financial Advisors LLC bought a new stake in shares of Oncology Institute during the 1st quarter worth approximately $88,000. 36.86% of the stock is currently owned by institutional investors and hedge funds.

Oncology Institute Price Performance

Shares of NASDAQ TOI opened at $0.47 on Monday. The company has a fifty day moving average price of $0.55 and a 200 day moving average price of $1.32. The firm has a market cap of $34.99 million, a PE ratio of -0.58 and a beta of 0.64. The company has a current ratio of 3.09, a quick ratio of 2.83 and a debt-to-equity ratio of 2.14. Oncology Institute has a 1-year low of $0.41 and a 1-year high of $2.66.

Oncology Institute (NASDAQ:TOI) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.10). Oncology Institute had a negative return on equity of 109.10% and a negative net margin of 20.28%. The firm had revenue of $94.67 million for the quarter, compared to analyst estimates of $95.17 million. During the same period in the prior year, the company earned ($0.10) earnings per share. Research analysts predict that Oncology Institute will post -0.63 earnings per share for the current fiscal year.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.